

Table 1: MAY2013-01-01 (MUC1 Colon) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
CELLS	Screen	1.66	1.01
	Week 2	1.61	1.01
	Week 10	1.77	1.00
	Week 12	1.82	1.01
	Week 52	1.75	1.01
	Week 55	1.71	1.00
	Week 156	1.58	1.02
PLASMA	Screen	1.04	1.18
	Week 2	1.02	1.21
	Week 10	1.00	1.22
	Week 12	1.00	1.29
	Week 52	1.00	1.30
	Week 55	1.02	1.33
	Week 156	1.02	1.57

Table 2a: MAY2013-02-02 (Erlotinib Liver) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
PLASMA	Baseline Ext/Int	4.65	0.94
	Post Interv Ext	4.53	0.89
SERUM	Baseline Ext/Int	3.78	0.92
	Post Interv Ext	3.80	0.87
WBC	Baseline Ext/Int	1.00	1.00
	Post Interv Ext	1.00	1.00

Table 2b: MAY2013-02-02 (Erlotinib Liver) Average core count for TISSUE Preserved in RNAlater

		Number of Tissue Cores by Subject
		Mean
Material Type	Visit	
TISSUE Preserved in RNAlater	Baseline Ext/Int	1.00
	Post Interv Ext	1.00

Table 3a: MAY2016-07-01 (Erlotinib HCL Duodenum) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
PLASMA	Baseline - Ext / Baseline - Int	9.18	1.00
	Month 3 - Ext / Month 3 - Int	8.85	1.00
	Month 6 - Ext / Month 6 - Int	8.93	1.00
	ET - Ext	9.00	1.00
SERUM	Baseline - Ext / Baseline - Int	3.85	1.00
	Month 3 - Ext / Month 3 - Int	3.90	1.00
	Month 6 - Ext / Month 6 - Int	3.81	1.00
	ET - Ext	4.00	1.00
URINE	Baseline - Ext / Baseline - Int	1.01	43.69
	Month 3 - Ext / Month 3 - Int	1.00	47.51
	Month 6 - Ext / Month 6 - Int	1.00	43.46
	ET - Ext	1.00	50.00
WBC	Baseline - Ext / Baseline - Int	1.01	0.97
	Month 3 - Ext / Month 3 - Int	1.00	0.79
	Month 6 - Ext / Month 6 - Int	1.00	0.89
	ET - Ext	1.00	1.40

Table 3b: MAY2016-07-01 (Erlotinib HCL Duodenum) Average slide count for TISSUE

		Number of Slides by Subject
		Mean
Material Type	Visit	
TISSUE	Baseline - Ext / Baseline - Int	7.35
	Month 6 - Ext / Month 6 - Int	7.62
	ET - Ext	10.00

Table 4: NWU2013-01-03 (Telapristone Breast) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
BUFFY CT	Time Point #1 Screening Visits 1 and 2, Pregnancy Test Visit	1.47	0.50
	Time Point #2 Intervention Time Point	1.00	0.50
	Time Point #3 Study Visit 1 Time Point	1.00	0.50
PLASMA	Time Point #1 Screening Visits 1 and 2, Pregnancy Test Visit	3.28	0.99
	Time Point #2 Intervention Time Point	3.00	1.00
	Time Point #3 Study Visit 1 Time Point	1.24	0.56
SERUM	Time Point #1 Screening Visits 1 and 2, Pregnancy Test Visit	3.05	0.89
	Time Point #2 Intervention Time Point	3.00	0.83
	Time Point #3 Study Visit 1 Time Point	2.53	0.85

Table 5a: NWU2014-04-01 (Simvastatin Pancreas) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
BLD CLOT	Baseline Testing - Visit 1	1.00	1.06
	Intervention - Visit 2	1.00	1.29
	Intervention - Visit 3	1.00	2.38
BUFFY CT	Baseline Testing - Visit 1	1.29	0.61
	Intervention - Visit 2	1.29	0.64
	Intervention - Visit 3	1.50	0.63
PLASMA	Baseline Testing - Visit 1	6.71	0.76
	Intervention - Visit 2	7.57	0.64
	Intervention - Visit 3	8.67	0.56
RBC	Baseline Testing - Visit 1	2.43	1.04
	Intervention - Visit 2	2.86	1.01
	Intervention - Visit 3	2.50	1.34
SECRETN	Screening 2	9.25	0.38
	Screening 2.10 (time point 10 minutes)	18.00	0.76
	Screening 2.15 (time point 15 minutes)	23.00	0.50
	Screening 2.20 (time point 20 minutes)	18.00	0.73
	Screening 2.30 (time point 30 minutes)	13.50	1.09
	Screening 2.45 (time point 45 minutes)	13.63	1.08
	Screening 2.60 (time point 60 minutes)	13.25	1.09
	Intervention - Visit 2	9.00	0.42
	Intervention - Visit 2.10 (time point 10 minutes)	18.00	0.89

(Continued)

Table 5a: NWU2014-04-01 (Simvastatin Pancreas) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
SECRETN	Intervention - Visit 2.15 (time point 15 minutes)	23.75	0.50
	Intervention - Visit 2.20 (time point 20 minutes)	18.00	0.84
	Intervention - Visit 2.30 (time point 30 minutes)	16.43	1.03
	Intervention - Visit 2.45 (time point 45 minutes)	16.14	1.06
	Intervention - Visit 2.60 (time point 60 minutes)	16.14	1.05
	Intervention - Visit 3	7.75	0.49
	Intervention - Visit 3.10 (time point 10 minutes)	18.00	1.12
	Intervention - Visit 3.15 (time point 15 minutes)	24.00	0.52
	Intervention - Visit 3.20 (time point 20 minutes)	18.00	1.13
	Intervention - Visit 3.30 (time point 30 minutes)	18.00	0.91
	Intervention - Visit 3.45 (time point 45 minutes)	18.00	0.95
	Intervention - Visit 3.60 (time point 60 minutes)	18.00	0.96
	SERUM	Baseline Testing - Visit 1	4.86
Intervention - Visit 2		4.29	0.95
Intervention - Visit 3		4.67	0.94

Table 5b: NWU2014-04-01 (Simvastatin Pancreas) Average unit count for STOOL

		Number of Units by Subject
		Mean
Material Type	Visit	
STOOL	Baseline Testing - Visit 1	4.00
	Intervention - Visit 2	4.00
	Intervention - Visit 3	4.00

Table 6a: NWU2015-06-04 (4-Hydroxytamoxifen, Tamoxifen Citrate Breast) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
PLASMA	HTCB Baseline	7.26	0.91
	HTCB Visit 1	5.62	0.85

Table 6b: NWU2015-06-04 (4-Hydroxytamoxifen, Tamoxifen Citrate Breast) Average FFPE tissue count

		FFPE Tissue Count by Subject
		Mean
Material Type	Visit	
FFPE TISSUE	HTCB Visit 1	3.26

Table 7: NWU2017-09-01 (NWU-Endoxifen Breast) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
BUFFY CT	EDB Baseline	2.28	0.88
	EDB Visit 2	2.31	0.83
PLASMA	EDB Baseline	11.88	0.91
	EDB Visit 2	10.14	0.87

Table 8a: UW12013-00-01 (Pomegranate Prostate) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
PLASMA	PGP Baseline	6.86	0.97
	WEEK 13	6.78	0.96
	WEEK 26	6.81	1.00
	WEEK 39	6.81	0.98
	WEEK 52	6.81	0.96
SERUM	PGP Baseline	4.00	0.67
	WEEK 13	2.00	0.59
	WEEK 26	3.85	0.69
	WEEK 39	2.08	0.69
	WEEK 52	3.96	0.79
URINE	PGP Baseline	2.93	1.00
	WEEK 13	2.89	1.00
	WEEK 26	2.85	1.00
	WEEK 39	2.88	1.00
	WEEK 52	2.89	1.00

Table 8b: UWI2013-00-01 (Pomegranate Prostate) Average slide count for TISSUE

		Number of Slides by Subject
		Mean
Material Type	Visit	
TISSUE	PGP Baseline	22.54
	WEEK 52	19.46